Torrent Pharmaceuticals - Public Comps and Valuation Multiples

Torrent Pharmaceuticals Overview

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.

Founded

1972

HQ

Employees

17.3K+

Website

torrentpharma.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.4B

LTM EBITDA $462M

EV

$15.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Torrent Pharmaceuticals Financials

As of December 2025, Torrent Pharmaceuticals reported last 12-month revenue of $1.4B and EBITDA of $462M.

In the same period, Torrent Pharmaceuticals generated $1.1B in LTM gross profit and $258M in net income.

See Torrent Pharmaceuticals valuation multiples based on analyst estimates

Torrent Pharmaceuticals P&L

In the most recent fiscal year, Torrent Pharmaceuticals reported revenue of $1.3B and EBITDA of $414M.

Torrent Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Torrent Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$1.4B	XXX	$1.3B	XXX	XXX	XXX
Gross Profit	$1.1B	XXX	$938M	XXX	XXX	XXX
Gross Margin	76%	XXX	75%	XXX	XXX	XXX
EBITDA	$462M	XXX	$414M	XXX	XXX	XXX
EBITDA Margin	33%	XXX	33%	XXX	XXX	XXX
EBIT	$370M	XXX	$326M	XXX	XXX	XXX
EBIT Margin	26%	XXX	26%	XXX	XXX	XXX
Net Profit	$258M	XXX	$213M	XXX	XXX	XXX
Net Margin	18%	XXX	17%	XXX	XXX	XXX
Net Debt	XXX	XXX	$273M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Torrent Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.4B. EBITDA for the last twelve months was $462M. In the most recent fiscal year, Torrent Pharmaceuticals achieved $1.3B in revenue and $414M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$1.4B	Analyst estimates available to subscribers	$1.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.1B	Analyst estimates available to subscribers	$938M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	75.9% gross margin	Analyst estimates available to subscribers	74.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$462M	Analyst estimates available to subscribers	$414M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	32.9% EBITDA margin	Analyst estimates available to subscribers	32.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$370M	Analyst estimates available to subscribers	$326M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	26.3% EBIT margin	Analyst estimates available to subscribers	25.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$258M	Analyst estimates available to subscribers	$213M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	18.3% net profit margin	Analyst estimates available to subscribers	16.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$273M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Torrent Pharmaceuticals

This financial data table provides comprehensive performance metrics for Torrent Pharmaceuticals, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Torrent Pharmaceuticals generated $1.4B in revenue over the last twelve months.
The company achieved $462M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.1B.
Net income over the last twelve months reached $258M.

Fiscal Year Performance

In the most recent fiscal year, Torrent Pharmaceuticals reported $1.3B in total revenue.
Fiscal year EBITDA was $414M.
The company maintained a gross profit margin of 74.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 32.9%.
Net profit margin reached 16.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Torrent Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Torrent Pharmaceuticals Stock Performance

Torrent Pharmaceuticals has current market cap of INR 1.36T (or $15.1B), and EV of INR 1.37T (or $15.3B).

Market Cap Evolution

Torrent Pharmaceuticals Stock Data

As of January 15, 2026, Torrent Pharmaceuticals's stock price is INR 4004 (or $45).

See Torrent Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$15.3B	$15.1B	XXX	XXX	XXX	XXX	$0.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Torrent Pharmaceuticals Valuation Multiples

Torrent Pharmaceuticals's trades at 10.9x EV/Revenue multiple, and 33.1x EV/EBITDA.

See valuation multiples for Torrent Pharmaceuticals and 15K+ public comps

Torrent Pharmaceuticals Financial Valuation Multiples

As of January 15, 2026, Torrent Pharmaceuticals has market cap of $15.1B and EV of $15.3B.

Equity research analysts estimate Torrent Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Torrent Pharmaceuticals has a P/E ratio of 58.6x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$15.1B	XXX	$15.1B	XXX	XXX	XXX
EV (current)	$15.3B	XXX	$15.3B	XXX	XXX	XXX
EV/Revenue	10.9x	XXX	10.9x	XXX	XXX	XXX
EV/EBITDA	33.0x	XXX	33.1x	XXX	XXX	XXX
EV/EBIT	41.3x	XXX	41.4x	XXX	XXX	XXX
EV/Gross Profit	14.3x	XXX	n/a	XXX	XXX	XXX
P/E	58.6x	XXX	58.9x	XXX	XXX	XXX
EV/FCF	68.3x	XXX	68.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Torrent Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Torrent Pharmaceuticals Margins & Growth Rates

Torrent Pharmaceuticals's last 12 month revenue growth is 14%

Torrent Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $35K for the same period.

Torrent Pharmaceuticals's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Torrent Pharmaceuticals's rule of X is 68% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Torrent Pharmaceuticals and other 15K+ public comps

Torrent Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	14%	XXX	13%	XXX	XXX	XXX
EBITDA Margin	33%	XXX	33%	XXX	XXX	XXX
EBITDA Growth	19%	XXX	16%	XXX	XXX	XXX
Rule of 40	47%	XXX	47%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	68%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$35K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	11%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	49%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial